Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

* eFFECTOR Therapeutics Inc  EFTR.OQ  reported a quarterly
adjusted loss of $3.42​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-5.50.  The mean expectation of
two analysts for the quarter was for a loss of $1.65 per share.
Wall Street expected results to range from $-3.21 to -9 cents
per share.
    * Reported revenue was zero​; analysts expected zero. 
    * eFFECTOR Therapeutics Inc's reported EPS for the quarter
was a
loss of $3.42​.
    * The company reported a quarterly loss of $9.13 million.
    * eFFECTOR Therapeutics Inc shares had risen by 5.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 45% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $22.50 
This summary was machine generated from LSEG data March 25 at
09:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.65          -3.42          Missed
 Sep. 30 2023      -3.08          -3.25          Missed
 Jun. 30 2023      -4.94          -4.25          Beat
 Mar. 31 2023      -3.40          -6.00          Missed

Recent news on Effector Therapeutics

See all news